Table 1.

CA-125 contents (U/ml) in serum, and cervical and vaginal secretions in healthy women and women with endometrial diseases.

Group	Number of subjects	CA-125 (U/ml)
		Serum	Cervical secretion	Vaginal secretion
Normal
Proliferative phase	24	16.80±2.99	483.56±58.21a	114.70±19.86a,b
Secretory phase	29	19.16±3.56	500.65±61.05a	124.00±25.63a,b
Non-functional polyps	24	22.18±5.03	796.03±141.14a	178.90±34.07a,b
Hyperplasia
Simple hyperplasia	24	18.98±2.76	518.12±70.28a	122.76±25.48a,b
Complex hyperplasia	21	36.41±14.34c	1220.39±684.88a,c	497.76±379.15a,b,c
Endometrial cancer
Grade 1	10	37.12±16.74d	950.56±58.73a,d	300.78±196.42a,b,d,e
Grade 2	9	43.12±13.58d	1806.16±927.97a,d,e	892.30±365.04a,b,d
Grade 3	7	26.77±3.64e	852.73±85.75a,e	271.90±75.86a,b,d,e
Subtotal	26
Total	148

^aP<0.05, serum vs. cervical or vaginal secretion;

^bP<0.05, cervical vs. vaginal secretion;

^cP<0.05, complex vs. simple hyperplasia, normal or polyps;

^dP<0.05, cancer vs. normal or simple hyperplasia;

^eP<0.05, grade II vs. III or grade I vs. II.